NCT06398925View on ClinicalTrials.gov

Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

September 25, 2023

Study Completion Date

September 25, 2023

Conditions
Healthy
Interventions
DRUG

OCT461201 50 mg

Oral capsule

DRUG

OCT461201 100 mg

Oral capsule

DRUG

OCT461201 150 mg

Oral capsule

DRUG

OCT461201 450 mg

Oral capsule

DRUG

Placebo

Placebo capsule

Trial Locations (1)

CF48 4DR

Simbec-Orion, Merthyr Tydfil

Sponsors

Collaborators (1)

Simbec-Orion Group
All Listed Sponsors
collaborator

Simbec-Orion Group

INDUSTRY

lead

Oxford Cannabinoid Technologies Holdings PLC

INDUSTRY